Abraxane for endometrial cancer – pro
Paclitaxel has consistently shown single-agent response rates of greater than 20% in previously treated endometrial cancer, even when administered in patients with prior cytotoxic chemotherapy. This leads many physicians to consider the peg0paclitaxel, a drug that is very similar and less toxic to be effective in endometrial cancer as well. However, there are much fewer studies supporting per-paclitaxel in this disease. NCCN does not list this drug and it recommends palliatuive care beyond second line.
Fader and Rose (2009) examined the effects of Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel. A total of 5 patients with gynecologic cancers (cervical cancer, n = 1; endometrial cancer, n = 2; and ovarian cancer, n = 2) received Abraxane after having a hypersensitivity reaction to paclitaxel. All 5 patients tolerated Abraxane well, experiencing no reactions or major side effects to the drug. The authors concluded that Abraxane is well-tolerated in women with gynecologic cancer who have experienced a paclitaxel-associated hypersensitivity reaction. There are no randomized studies and I did not find guideline recomemndatiosn of this drug for endometrial cancer.
Fader AN1, Rose PG.Abraxane for the treatment of gynecologic cancer patients with severe hypersensitivity reactions to paclitaxel.
Int J Gynecol Cancer. 2009 Oct;19(7):1281-3.
Lheureux S, Wilson M, Mackay HJ. Recent and current Phase II clinical trials in endometrial cancer:review of the state of art. Expert Opin Investig Drugs. 2014 Jun;23(6):773-92
NCCN, Uterine Cancer 2015, ENDO-C and ENDO-9